Assenagon Asset Management S.A. Invests $17.79 Million in Soleno Therapeutics, Inc. $SLNO

Assenagon Asset Management S.A. acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 384,166 shares of the company’s stock, valued at approximately $17,787,000.

A number of other institutional investors have also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in Soleno Therapeutics during the 2nd quarter valued at about $25,000. Danske Bank A S purchased a new stake in Soleno Therapeutics in the third quarter valued at about $27,000. Aster Capital Management DIFC Ltd acquired a new stake in Soleno Therapeutics in the third quarter worth about $37,000. Quarry LP acquired a new stake in Soleno Therapeutics in the third quarter worth about $47,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Soleno Therapeutics during the third quarter worth about $67,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Oppenheimer cut their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Wells Fargo & Company lowered their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.60.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: Hagens Berman announces a securities class action alleging losses tied to Soleno’s DCCR disclosures. Read More.
• Negative Sentiment: Rosen Law Firm reminds investors of May 5, 2026 lead-plaintiff deadline and solicits clients. Read More.
• Negative Sentiment: Kessler Topaz issues investor alert for purchasers during the Class Period. Read More.
• Negative Sentiment: Bernstein Liebhard announces a shareholder class action filing and solicits participation. Read More.
• Negative Sentiment: Pomerantz LLP issues investor alert and contact information for potentially affected shareholders. Read More.
• Negative Sentiment: Portnoy Law Firm announces a class action covering purchases from March 6–Nov 4, 2025 and the May 5 deadline. Read More.
• Negative Sentiment: SueWallSt alerts investors and highlights alleged misrepresentation of DCCR safety timeline. Read More.
• Negative Sentiment: Robbins Geller files a class action and invites investors to seek lead-plaintiff status. Read More.
• Negative Sentiment: Glancy Prongay Wolke & Rotter notifies investors of opportunity to lead the securities fraud lawsuit. Read More.
• Negative Sentiment: Levi & Korsinsky alleges possible sham clinical-trial conduct in their investor alert. Read More.
• Negative Sentiment: Faruqi & Faruqi reminds investors of the May 5, 2026 class action deadline. Read More.
• Negative Sentiment: ClaimsFiler and other services remind large-loss investors about the lead-plaintiff deadline. Read More.
• Negative Sentiment: Kaplan Fox, Kahn Swick & Foti and other firms issue similar alerts and notices to investors. Read More. Read More.

Soleno Therapeutics Trading Up 0.1%

Shares of NASDAQ:SLNO opened at $31.86 on Friday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics, Inc. has a 52-week low of $30.11 and a 52-week high of $90.32. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of 138.53 and a beta of -3.16. The business has a 50-day moving average price of $38.77 and a 200-day moving average price of $48.95.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. Equities analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.